Biotech · Private company
Ensem Therapeutics
Track this companyFree. Adds Ensem Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ETX-636 dose escalationPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ETX-636 dose escalation in combination with fulvestrantPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ETX-636 dose expansion in combination with fulvestrantPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ETX-929 dose escalationPhase 2 · Metastatic Colorectal Cancer (CRC)ClinicalTrials.gov · fetched Nov 12, 2026
- ETX-929 dose escalation in combination with cetuximabPhase 2 · Metastatic Colorectal Cancer (CRC)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Oct 22, 2026ClinicalTrials.gov NCT07912593 · fetched Nov 12, 2026
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jun 10, 2025ClinicalTrials.gov NCT06993844 · fetched Nov 12, 2026